Delivery Order SPE2DR25D7063-SPE2DR26F3CUC
- Not listed
- The Defense Logistics Agency awarded a $2,447.64 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on December 1, 2025, with completion scheduled for December 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The contract will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adults 18 years and older, and...
- The Defense Logistics Agency awarded a $53,766.20 delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of HEPLISAV-B 20 mcg/0.5 ml syringes. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $143,366.66 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 9, 2025, with an ultimate completion date of September 10, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $1,955.95 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on December 12, 2025, with an ultimate completion date of December 15, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for prevention of hepatitis B...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,734.63 on November 20, 2025, for HEPLISAV-B 20 mcg/0.5 mL syringes. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of November 21, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine used for immunization of adults,...
- The Defense Logistics Agency awarded a delivery order valued at $1,173.57 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on December 17, 2025, with completion scheduled for December 18, 2025. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical....
- The Defense Logistics Agency awarded a $139,894.18 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 22, 2025, with completion scheduled for July 23, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The work will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $6,819.50 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on December 4, 2025, with completion targeted for December 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's facility in...
- The Defense Logistics Agency (DLA) awarded a $273,806 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 9, 2025, with completion expected by September 10, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing...
- The Defense Logistics Agency awarded a $2,347.14 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 ml syringes on December 9, 2025, with completion scheduled for December 10, 2025. This competitively awarded, firm fixed-price contract was issued without a set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for immunization of adults aged 18 and older,...
- SPE2DR25D7063Indefinite Delivery Contract
- SPE2DR25D7063-SPE2DR26F3CUCDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,129.52 to AmerisourceBergen Drug Corp on December 22, 2025, for the supply of HEPLISAV-B 20 mcg/0.5 mL syringes. This competitive award carries a firm fixed price structure with no set-aside designation and an ultimate completion date of December 23, 2025. The delivery will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for prevention of hepatitis B infection in adults. AmerisourceBergen, as a major pharmaceutical distributor and critical vendor for federal medical procurement, maintains an extensive portfolio of pharmaceutical products and medical supplies supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's demonstrated capability to meet federal procurement requirements through open competition, combined with its large IDC framework, positions it as a primary supplier for the military medical supply chain across multiple therapeutic domains and geographic regions worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1k | 12/21/25 |